Analysts Offer Insights on Healthcare Companies: Durect (DRRX) and Invitae (NVTA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Durect (DRRX) and Invitae (NVTA) with bullish sentiments.
In a report released yesterday, Francois Brisebois from Oppenheimer reiterated a Buy rating on Durect, with a price target of $8.00. The company’s shares closed last Tuesday at $1.79.
According to TipRanks.com, Brisebois is a 3-star analyst with an average return of 7.7% and a 35.1% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Diamedica Therapeutics, and Kala Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Durect with a $7.33 average price target.
See today’s analyst top recommended stocks >>
Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Invitae yesterday and set a price target of $48.00. The company’s shares closed last Tuesday at $31.50.
According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 47.1% and a 51.9% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Rocket Pharmaceuticals, and Sensei Biotherapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Invitae with a $50.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.